- Home
- SSRM vs IBRX Comparison
SSRM vs IBRX Comparison
Compare SSRM & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SSRM | IBRX |
|---|---|---|
| Founded | 1946 | 2014 |
| Country | United States | United States |
| Employees | 2900 | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 7.2B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | SSRM | IBRX |
|---|---|---|
| Price | $30.51 | $9.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $32.74 | $12.57 |
| AVG Volume (30 Days) | 3.1M | ★ 11.7M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $56.48 | $88.59 |
| Revenue Next Year | $4.31 | $131.15 |
| P/E Ratio | $14.37 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $11.70 | $1.95 |
| 52 Week High | $36.52 | $12.43 |
Technical Indicators
Market Signals| Indicator | SSRM | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.44 | 73.88 |
| Support Level | $28.41 | $6.69 |
| Resistance Level | $33.66 | $9.54 |
| Average True Range (ATR) | 1.48 | 0.56 |
| MACD | 0.15 | 0.25 |
| Stochastic Oscillator | 59.26 | 95.03 |
Price Performance
Historical ComparisonAbout SSRM SSR Mining Inc.
SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.